Resuscitation of newborn infants occurs in approximately 10% of the more than 100 million infants born annually worldwide. The techniques used during resuscitation, such as positive-pressure ventilation and supplemental oxygen, may revive many infants, but have the potential to harm their lungs. In recent years increasing attention has been applied to providing lung protection from the first breath. This paper reviews the currently available medical evidence concerning modifying aspects of delivery room management that are thought to mitigate lung injury. These include: F IO 2 < 1.0; early use of continuous positive airway pressure (CPAP) and PEEP; optimizing pressure and/or volume during ventilation; sustained inflations; need for and timing of surfactant therapy; and airway management of meconium-stained amniotic fluid. Although the evidence against 100% oxygen use is of low quality, it has been enough to alter the recommendations for oxygen use in the delivery room. It is suggested (not mandated) to use room air initially when resuscitating a termgestation infant, and to use F IO 2 < 1.0 in premature infants, with F IO 2 adjustments depending on oximetry values. Recent studies have not indicated better outcomes in premature infants in whom CPAP or PEEP is applied in the delivery room. Optimal peak ventilatory pressure and tidal volume have yet to be delineated. Although an intriguing therapy, sustained inflations have not been shown to markedly improve outcomes. Prophylactic use of surfactant in small, premature infants remains the accepted standard. Immediate placement on CPAP after surfactant instillation has yet to demonstrate clear-cut advantages. Finally, intrapartum oropharyngeal and nasopharyngeal suctioning of meconium-stained amniotic fluid does not improve outcomes in meconium-stained infants. Moreover, routine intubation and intratracheal suctioning of apparently vigorous meconiumstained infants do not improve outcomes. In summary, although multiple therapies are touted as protecting the lungs in the delivery room "from the first breath," to date there are scant supportive data.
Introduction
The transition from fetal to extrauterine life is complex. [1] [2] [3] Although approximately 90% of infants respond well to stimulation, warmth and suctioning, the remaining 10% may need additional interventions to achieve and sustain homeostasis. Ten to twenty percent of the latter require more aggressive interventions. During the intrapartum period, the fetus and newborn must mobilize the lung fluid in the airways and parenchyma. Two to 3 days prior to delivery, the secretion of lung fluid normally declines. The labor process further reduces extravascular lung water. Subsequent to birth, fluid is driven from the alveoli into the interstitium. Many infants fail to adequately "dry out" their lungs, particularly infants delivered via cesarean section. After parturition, the airways and the alveoli have to be inflated to exchange gas. Poor respiratory effort impedes this process. Preterm infants with insufficient surfactant will have widespread atelectasis. Small preterm infants and depressed or neurologically impaired termgestation infants may not be able to generate sufficient negative intrathoracic pressure to expand their airways. Pulmonary vascular resistance has to decline to allow a 10-fold increased flow of blood to the lungs. This decrease is modulated by increased oxygenation and adequate ventilation. Additionally, peripheral vascular resistance has to increase to increase systemic arterial blood pressure, which helps drive blood into the lungs, allowing the exchange of oxygen and carbon dioxide. The intrauterine fetal circulation changes to adapt to extrauterine life. In utero, the ductus arteriosus and foramen ovale serve as conduits of oxygenated blood from the right side of the heart to the systemic circulation. These pathways must functionally and then physiologically close once the newborn is cut off from placental flow with clamping of the umbilical cord. Failure of the ductus arteriosus and foramen ovale to adjust can result in shunting of the blood and adversely affect gas exchange.
Premature infants have particular difficulties in accomplishing normal transition. 4 Their lungs are structurally immature and frequently deficient in surfactant. They are less able to get rid of the copious intraluminal lung fluid present in utero. The lack of a stiff chest wall contributes to widespread atelectasis. Inflammation is frequently present in the lungs of these infants, compounding the effects of increased pulmonary vascular resistance and causing surfactant dysfunction. The majority of preterm infants less than 30 weeks gestation require extra assistance in the delivery room.
Typical interventions used to assist the neonate's transition are supplemental oxygen and continuous positive airway pressure (CPAP) or active ventilation, via face mask or endotracheal tube. Premature infants often receive exogenous surfactant in the minutes following birth. Most of the time these therapies work well, and the infant can sustain his or her own respirations and gas exchange within minutes. Nonetheless, these tools have the potential to adversely affect the lungs, the very organ that clinicians, with the best of intentions, have been trying to help.
Based on animal and human research, a number of mechanisms have been described that could injure lungs during resuscitation. Volutrauma refers to overdistention of areas of the lung that can occur with assisted ventilation. Inflammation and physical damage may be consequences. Even a few large manual breaths can cause injury. 5 Atelectrauma is injury due to repeated collapse and reopening of alveoli and the distal bronchioles. The air sacs are exposed to repeated shearing forces, with inflammation, membrane disruption, and surfactant dysfunction. The main mechanism producing atelectrauma is believed to be the use of inadequate PEEP, resulting in low residual volume and atelectasis. Biotrauma refers to injurious local and systemic inflammatory responses to physical stress. Finally, high F IO 2 could be toxic to the lungs. Oxygen free radicals may be formed and inflammation may occur. Neonates have less antioxidant capability than older children.
Historically, during resuscitation 100% oxygen has been used while ventilating neonates. 6 There has been recent recognition that this practice could have adverse consequences. Finally, meconium-stained amniotic fluid is found in approximately 12-15% of all births, and meconium may be aspirated either in utero or postnatally. Meconium can have direct toxic effects on the lung parenchyma itself, and the meconium aspiration syndrome may result in a need for substantial respiratory support, which could have deleterious effects on the lung. 7 A number of lung-protective strategies during newborn resuscitation have been proposed, which I will discuss in the body of this paper.
One of the goals of resuscitation is to provide sufficient oxygen perfusion of tissue. Oxygen is critical for life and is required for cell metabolism and growth. Even relatively short-term hypoxemia can have disastrous outcomes. Oxygen was first administered to a neonate in 1780. Since the 1940s, oxygen has been the most commonly used therapy in the delivery room and in the neonatal intensive care unit. 8 High F IO 2 for a prolonged period (days to weeks) is a major factor in the pathogenesis of major newborn morbidity, including retinopathy of prematurity and bronchopulmonary dysplasia (BPD). High F IO 2 leads to the production of oxygen free radicals such as superoxide, hydrogen peroxide, and the hydroxyl radical. These are highly reactive chemical species that can react with and injure almost every type of molecule in living cells. High F IO 2 may prolong the time to spontaneous crying and breathing, increase oxygen consumption, decrease minute ventilation, cause atelectasis, or alter cerebral circulation (decrease cerebral blood flow). [9] [10] [11] [12] [13] [14] [15] [16] [17] By contrast, too low an F IO 2 can cause persistent pulmonary hypertension of the newborn, hypoxic brain injury, multisystem organ dysfunction, and is more likely to keep the ductus arteriosus open.
Several trials have assessed the initial use of room air versus 100% oxygen in the resuscitation of newborns. [9] [10] [11] [12] [13] [14] Although the bulk of enrolled patients were of term gestation, infants as small as 1,000 g birth weight and 27 weeks gestation were included in 4 of the trials. [9] [10] [11] 14 In general, these studies indicated that using room air as a starting point during resuscitation resulted in similar outcomes to 100% oxygen. Most of the investigations found that infants resuscitated with room air took less time to have the onset of both their first breath and their first cry. Approximately one quarter of the room air-treated neonates needed to be switched to 100% oxygen after several minutes because of a failure to respond. There have been many criticisms of these investigations. The 4 trials done in developing countries [9] [10] [11] 14 were quasi-randomized, they enrolled patients into the treatment groups depending on whether it was an odd-number versus even-number day, and the investigators were not blinded to the F IO 2 children received. Two of the trials 10, 12 found trends toward higher mortality in the 100% oxygen groups. The other 4 studies, including the 2 performed in a developed country, 12, 13 did not find a similar trend. Two trials revealed increases in markers of oxidative stress (eg, serum levels of glutathione and superoxide dismutase) among those treated with 100% oxygen. Short-term neurological outcomes (assessed at 3-28 days) were reportedly equivalent in all 6 investigations. The 4 studies that enrolled preterm infants did not stratify outcomes by gestational age.
Sorely lacking in all of these reports were outcome data concerning major morbidity: chronic lung disease, persistent pulmonary hypertension, intracranial hemorrhage, cerebral white matter injury, necrotizing enterocolitis, patent ductus arteriosus, and retinopathy of prematurity. There was only one long-term follow-up study, of the infants in the largest trial. 15 Approximately one third of infants in that trial were subsequently assessed in an unblinded fashion at 18 -24 months following enrollment. The examiners were investigators from the original study and were not neurologists. They administered a questionnaire and examined the children. Cognition was not assessed. There were no differences in the outcomes between the groups in that limited follow-up.
The data generated by these studies have been controversial. Interestingly, a group of independent authors, using the aforementioned data, published meta-analyses in 2 separate reports published within months of each other and drew opposite conclusions. 16, 17 In their initial publication, a Cochrane Systematic Review, 16 they concluded that the evidence was insufficient to recommend room air over 100% oxygen. Several months later, using the same data and analytical methods, they concluded that room air should initially be used for resuscitating term and near-term infants, with oxygen as a backup. 17 Despite the limitations of the 6 investigations, the International Liaison Committee on Resuscitation recently revised its recommendations concerning the use of oxygen: "In term infants receiving resuscitation at birth with positive-pressure ventilation, it is best to begin with air rather than 100% oxygen. If, despite effective ventilation, there is no increase in heart rate, or if oxygenation (guided by oximetry) remains unacceptable, use of a higher concentration of oxygen should be considered." 18 This was stated to be a class IIb, level of evidence B recommendation, 19 meaning that it is an acceptable recommendation based on "weak" evidence (not excellent or good evidence). In the recently published 6th edition of the Textbook of Neonatal Resuscitation, published under the auspices of The Neonatal Resuscitation Program, appears a table of preductal saturation target ranges during resuscitation (Table 1) . 19, 20 If an infant's oxygen saturation is below the lower limit at specified time points, it is recommended that oxygen should be administered, via blender, in concentration sufficient to achieve the target range, and that use of room air is advocated (but not mandated) at the initiation of resuscitation in a term infant. 20 What should one do concerning supplemental oxygen when resuscitating a premature infant? In the 4 aforementioned studies, the premature infants' outcomes were not delineated. The optimal oxygen saturation for the resuscitation, stabilization, and ongoing care of the very preterm infant remains undefined. 21 There have been several small, randomized controlled trials of lower versus higher F IO 2 during neonatal resuscitation of preterm infants. [22] [23] [24] [25] [26] [27] Only one of the trials used room air as their initial low-F IO 2 group, 22 and every one of those infants needed supplemental oxygen within 2-5 min of birth. Similar to the termgestation infant trials, there appeared to be fewer markers of oxidative stress among infants treated with lower F IO 2 . 23, 25, 27 None of those trials were adequately powered to evaluate important long-term outcomes such as survival, neurodevelopmental disability, or BPD. For premature infants the International Liaison Committee on Resuscitation recommends: "Because many preterm infants of Ͻ 32 weeks gestation will not reach target saturation on room air, blended oxygen and air may be given judiciously, and is ideally guided by pulse oximetry. Both hyperoxemia and hypoxemia should be avoided." 18 The new 6th edition of the Textbook of Neonatal Resuscitation advocates "something less than 100% oxygen, but more than 21% oxygen for a preterm baby." 20 In my unit, when resuscitating a premature infant we start with an initial F IO 2 of 0.50 and adjust upward or downward depending on the preductal oxygen saturation during the resuscitation process. A large well designed randomized controlled blinded prospective trial is needed to determine the appropriate F IO 2 when initiating resuscitation.
In his classic tome Retrolental Fibroplasia: A Modern Parable, 28 the late William Silverman, the "grandfather" of randomized controlled trials in neonates, related a story of oxygen restriction in preterm infants. During the 1950s it was recognized that premature infants given high F IO 2 during hospitalization were more likely to develop the serious, potentially blinding condition of retrolental fibroplasia (ie, retinopathy of prematurity). There was subsequent widespread restriction of oxygen use in premature infants. Only after the ensuing 5 years was it recognized that this oxygen restriction had the unintended consequence of increasing mortality and cerebral palsy in survivors. Additionally, several large trials are underway to compare 2 different target oxygen saturation ranges (85-89% and 91-95%) in premature infants Ͻ 28 weeks gestation, and Stenson 29 recently examined mortality data from more than 3,600 infants in those trials. He found a significant 8.5% higher frequency of death among infants in the lower target saturation range, and the difference appeared to be mainly due to more deaths from brain injury and necrotizing enterocolitis. I would caution clinicians to be judicious about jumping on the low-F IO 2 or room air bandwagon.
CPAP and Sufficient PEEP
The lungs of preterm infants at birth are surfactant deficient, so it may be difficult for them to achieve adequate functional residual capacity (FRC) and maintain open alveoli and distal airways. The delivery room use of CPAP or PEEP of at least 4 -5 cm H 2 O has been advocated to assist in lung expansion, establish FRC, and improve oxygenation. 1, 3, 4 Early use of CPAP in the delivery room, in both preterm and term-gestation infants, has been enthusiastically advocated by many clinicians, 20 but there is a scarcity of data supporting this approach.
Finer et al 30 assessed the effects of CPAP or PEEP in infants Ͻ 28 weeks gestation. One-hundred four infants were randomized to either no CPAP and 100% oxygen or to CPAP/PEEP via a T-piece resuscitator (NeoPuff, Fisher & Paykel, Auckland, New Zealand). Delivery room intubation was needed in 41% of the controls and 49% of the CPAP/PEEP group, whereas there was no significant difference in intubation at some other time during hospitalization (78% vs 82%). Death was more likely in the CPAP/ PEEP group (27% vs 13%, P ϭ .07), as was the incidence of pneumothoraces (13% vs 9%, difference not significant). The frequency of chronic lung disease was not assessed.
Morley and colleagues 31 randomized more than 600 premature infants (25-28 weeks gestation) in the delivery room to CPAP (8 cm H 2 O) or to intubation and ventilation. Although the CPAP group had a trend toward a lower combined end point of death or BPD (34% vs 39%), the difference was not significant. In the CPAP group there was less use of surfactant, and the subjects averaged one day less of mechanical ventilation. Unfortunately, the CPAP-treated infants were significantly more likely to develop pneumothoraces (9% vs 3%, P Ͻ .001).
The SUPPORT trial 32 involved infants born between 24 and 27 weeks gestation. The infants were randomized to either intubation and surfactant within 1 hour of birth, or to CPAP (5 cm H 2 O) initiated in the delivery room. The CPAP patients could subsequently be intubated and receive surfactant if they fulfilled certain criteria (F IO 2 Ͼ 0.50, P aCO 2 Ͼ 65 mm Hg, or hemodynamic instability). There was a combined primary outcome: death or BPD. Eightythree percent of the CPAP group subsequently required intubation. The CPAP group had approximately 3 fewer days of mechanical ventilation. Nevertheless, there were no statistically significant differences in death, BPD, or the combined end point of death or BPD.
Members of the Vermont Oxford Network 33 performed a prospective randomized controlled trial of 3 approaches in the delivery room. Preterm infants (n ϭ 648) of 26 -29 weeks gestation were randomized to either: prophylactic surfactant followed by ventilation; intubation and surfactant followed by rapid extubation to nasal CPAP; or early stabilization on nasal CPAP. The nasal CPAP group was less likely to receive surfactant or to be ventilated during the first week of life. However, there were no differences between groups in the outcomes of death, chronic lung disease, or other complications of prematurity.
Finally, the Brazilian Network on Neonatal Research 34 also assessed early use of nasal CPAP in the delivery room. They randomized 173 infants (birth weight
I would conclude from the aforementioned trials that the current evidence to support routine use of CPAP/PEEP in the delivery room among preterm infants is less than compelling. If we examine the major end points of death or BPD, the use of CPAP/PEEP in the delivery room does not influence outcomes. Finally, there are virtually no scientific data on the delivery room use of CPAP or PEEP in term-gestation infants. The International Liaison Committee on Resuscitation report 18 and the Neonatal Resuscitation Program guidelines 20 suggest that the use of CPAP/ PEEP should reflect local expertise and preferences.
Positive-Pressure Ventilation and Sustained Inflations
The depressed infant frequently requires positive-pressure ventilation. In an animal model, 5 as few as 6 large manual breaths (35-40 mL/kg) are enough to cause widespread histologic lung injury. Unfortunately, there is no single appropriate tidal volume or peak inspiratory pressure that is appropriate for all infants, as lung compliance varies from infant to infant. Additionally, spontaneously breathing infants may initially generate extraordinarily high negative intrathoracic pressure (up to 70 cm H 2 O) in an effort to achieve FRC. 2 No trials have compared the effect on outcomes of different inflation pressures or tidal volumes during initial stabilization of preterm infants. 35 In general, the initial peak inflating pressure used, in both premature and term infants, should be individualized to achieve an increase in heart rate or movement of the chest. Higher inflation pressure is typically needed for the initial few breaths to open the lungs, but the clinician should be cognizant that with subsequent breaths lower peak inflating pressure or tidal volume is probably required. There are virtually no data on pulmonary mechanics (eg, compliance, resistance, pressure-volume relationships) during resuscitation of neonates. In term infants an initial inflating pressure of approximately 30 cm H 2 O is sufficient to improve heart rate or chest expansion, whereas in preterm infants 20 -25 cm H 2 O is generally effective. 18 There have been no scientific investigations of different tidal volumes during or immediately after resuscitation. Clearly, clinical trials are needed to assess various strategies in establishing lung volume, FRC, shortterm outcomes (eg, oxygenation, ventilation, spontaneous breathing), and long-term outcomes (eg, mortality, chronic lung disease, other markers of lung injury).
Sustained inflations for the first several breaths of manual ventilation are a popular method to assist the formation of FRC during resuscitation. 35 This concept dates back 3 decades. 36 Most work has been done in the extremelylow-birth-weight population. Linder and colleagues 37 used sustained inflations of 20 -25 cm H 2 O for 15-20 seconds, followed by CPAP, and compared the outcomes to historical controls. The infants were less likely to require intubation, either in the delivery room or thereafter. However, when Linder et al 38 subsequently performed a randomized controlled trial to compare their sustained-inflations strategy to routine intubation/ventilation, they found no differences in the number of infants subsequently requiring intubation or mechanical ventilation.
Te Pas and Walther 39 randomized 207 preterm infants who required resuscitation to either a sustained inflation of 20 cm H 2 O for 10 seconds or to conventional positivepressure ventilation with a self-inflating bag and mask with an initial inflation pressure of 30 -40 cm H 2 O. The sustained-inflation group was significantly less likely to require intubation within the first 72 hours of life (37% vs 51%), had a shorter duration of ventilation, and were less likely to develop BPD (22% vs 34%).
Lista and colleagues 40 compared a group of premature infants treated with sustained inflations (25 cm H 2 O for 15 s) to a historical cohort treated with CPAP at 5 cm H 2 O. The sustained-inflations group was less likely to require mechanical ventilation or to develop BPD. However, the fact that the study was not prospective, randomized, or controlled limits its usefulness. Over the past 30 years there have been virtually no investigations, in term-gestation infants, of sustained inflations versus other respiratory management techniques. Therefore, although sustained inflations appear to be an intriguing method of opening the lung and achieving an initial FRC, I do not believe there are currently enough data to support the routine use of sustained inflations during resuscitation of preterm or termgestation infants. The International Liaison Committee on Resuscitation report 18 and the Neonatal Resuscitation Program guidelines 20 suggest that decisions regarding variable inflation times, such as sustained inflations, should reflect local expertise and preferences.
Surfactant
Exogenous surfactant therapy has been an integral part of neonatal intensive care unit care for the past 20 years. In the preterm infant population, surfactant use has sub-stantially decreased mortality. However, it has not affected BPD incidence. Premature lung disease (respiratory distress syndrome) results from surfactant deficiency in a structurally immature lung that is easily injured. 41 The major surfactants used throughout the world in 2011 are animal-derived, generally from a mince or lavage of either bovine or porcine lungs. 42 Outside the preterm population, there are several disorders in which surfactant deficiency or inactivation occurs (eg, meconium aspiration syndrome, pneumonia). Several trials have found exogenous surfactant effective in nonpremature infants. In a systematic review, Soll and colleagues 43 concluded that prophylactic use (generally defined as within the first 15 min of life) of exogenous surfactant in premature infants is better than selective (rescue) use of surfactant among infants Ͻ 29 weeks gestation (fewer pneumothoraces, decreased mortality, less pulmonary interstitial emphysema). Prophylaxis is generally done in the delivery room soon after birth. Most of the data supporting the superiority of prophylaxis come from studies performed in the late 1980s and early 1990s, which was before the widespread use of antenatal corticosteroids (to hasten lung maturation) and newer methods of support (eg, high-frequency ventilation) and modes of conventional ventilation (eg, synchronization, volume-targeting, pressure support). Additionally, many believe that CPAP at a sufficient level accomplishes results similar to exogenous surfactant (by opening the alveoli and improving oxygenation). Thus, frequently clinicians are now delaying surfactant administration until they are certain respiratory distress syndrome is established and is more than mildly debilitating.
The surfactant approach used in the Intubation, Surfactant, Extubation to CPAP (INSURE) trial has been widely practiced in Europe over the past decade 44 and has gained popularity in other areas of the world. Although most randomized controlled trials of the INSURE approach have found a short-term decrease in the need for mechanical ventilation, no differences in mortality or chronic lung disease have been described. 44 The Vermont Oxford Network trial 33 found no advantages with the INSURE approach. The current place of INSURE therapy during resuscitation needs to be clarified. Do we need new surfactants? With currently available animal-derived surfactants, up to 15% of premature infants fail to respond. In the commercially available surfactants there is wide variability (Ϯ 50%) of target surfactant protein level, and potential immunogenicity and infection risks. Synthetic surfactant that contains surfactant protein mimics may be one way of improving our current therapies. 42 In addition, noninvasive delivery (eg, aerosolization or via laryngeal mask airway) may prove useful in certain situations.
Although surfactant therapy is used daily in delivery rooms around the world in premature infants, to date neither the International Liaison Committee on Resuscitation nor the Neonatal Resuscitation Program have addressed surfactant use in the delivery room. Thus, clinicians have to make their own decisions on the timing of surfactant therapy in the vulnerable population of preterm infants.
Oropharyngeal and Intratracheal Suctioning of Meconium-Stained Amniotic Fluid
Prevention of meconium aspiration syndrome 7 has long been a goal of clinicians in the delivery room. Approximately 12-15% of all newborn infants are born through meconium-stained amniotic fluid, and, historically, 3-10% of those patients develop meconium aspiration syndrome. 7, 45, 46 It is associated with substantial morbidity, such as need for mechanical ventilation, persistent pulmonary hypertension of the newborn, need for extracorporeal membrane oxygenation, long-term abnormal pulmonary dysfunction, and death. Histological features of meconium aspiration syndrome include inflammation, obstruction of airways, and areas of atelectasis alternating with overexpansion. Meconium can inactivate endogenous surfactant and can cause direct injury to the lung parenchyma, including necrosis and hemorrhage. Multiple maneuvers have been used in the delivery room to prevent meconium aspiration 7, 45, 46 The hope has been that removal of meconium-stained amniotic fluid would mitigate its effects on the infant's lungs.
For a 25-year period starting in the mid-1970s, the routine teaching was to intubate all meconium-stained infants and suction out the trachea. 7 We performed a large randomized controlled trial to assess whether this maneuver would be effective in apparently vigorous meconiumstained neonates. 45 We enrolled more than 2,000 infants. If they were thought to be vigorous immediately after delivery (heart rate Ͼ 100 beats/min, good respiratory effort, normal tone), they were randomized to either intubation and tracheal suctioning or to expectant management. We found no differences in outcomes between the 2 groups. Additionally, since the mid-1970s it was routine when delivering a meconium-stained infant to suction out the nasopharynx and oropharynx before the head and shoulders are delivered. 7 The thinking was that removing the meconium-stained fluid before the child's first breath would prevent aspiration. We performed a large, randomized controlled trial to assess whether this therapy was truly effective. 46 We enrolled more than 2,000 meconium-stained infants who were randomized to either intrapartum oropharyngeal and nasopharyngeal suctioning or to expectant management. There were no differences in outcomes between the 2 groups. These results have contributed to the thinking that meconium aspiration syndrome is often a result of in utero aspiration of meconium-stained amniotic fluid and cannot be prevented by intrapartum or postnatal therapies. There remains a major question of whether the depressed meconium-stained infant benefits from intratracheal suctioning, as has long been recommended by the International Liaison Committee on Resuscitation and the Neonatal Resuscitation Program. Over the past decade there have been many discussions about performing a definitive clinical trial, but at present there are no trials underway to answer this question.
Summary
Newly born infants frequently need assistance to establish normal respirations, but many resuscitation maneuvers can injure the lungs of preterm and term-gestation neonates. I have discussed the rationale for preventing such injury and the evidence basis for what we do. To date, however, there are no good scientific data supporting changes in our current delivery room management of neonates that can clearly increase lung protection and improve overall outcomes.
Discussion
Walsh: It's my understanding that neonates lack antioxidants, and you talked about the negative impact of free radicals. Are there any studies that support the use of antioxidants in the delivery room?
Wiswell: None have been specifically used in the delivery room. For the antioxidants used later in neonates there is little evidence that they're effective for any lung disorders such as respiratory distress syndrome or BPD. Have any of you used superoxide dismutase (SOD), administered down the endotracheal tube? I was involved with some of the initial work in the 1990s. As an aside, our therapists said that "SOD" must stand for "sudden onset of death," because frequently the babies who received it desaturated and became bradycardic.
Walsh:
With the approval of the use of F IO 2 Ͻ 1.0 in the delivery room, do you think we'll use more recruitment maneuvers for better management of FRC, to keep oxygen saturation up?
Wiswell: Hopefully, the latter. I'm a firm believer in achieving FRC but not overdoing it. Once you've achieved good FRC with an optimal mean airway pressure, you should be achieving good oxygenation. This can be a delicate balance, though. One must closely assess oxygenation in the delivery room. I've seen some proponents of using room air refuse to use any higher F IO 2 while resuscitating a baby for longer than 3 minutes without there being an improvement in the child's condition. One has to be cognizant that ineffective prolonged use of room air could result in morbidity or mortality.
DiBlasi: You mentioned that babies don't really have a difficult time inhaling particles into their lungs: mainly meconium. In the premature population is there any interest in suctioning the oropharynx as the baby's head presents at the perineum, injecting surfactant into the airway prior to the first breath, so in the initial breath the surfactant would be distributed throughout the lung? Maybe we would not have to intubate as much? There are compelling animal data to support doing that, but where are we right now with humans?
Wiswell: Some small studies have addressed therapies like that, including obstetricians trying to do this in babies that are still inside the uterus. They tried to thread a catheter into the fetus's mouth or throat and then instill surfactant that way. A couple of small trials have tried instilling surfactant before the infant's first breath. Some people have tried to do it noninvasively, without intubating. However, there's not a lot of information yet. It's an intriguing approach, and you'd think you'd have more success doing that, unless the baby has taken some big breaths already.
Brown: You mentioned the SUP-PORT trial, in which we were a primary center. You said that intubation surfactant wasn't found to be any better, but you could look at it the other way, which is that nasal CPAP was just as good. It's somewhat shocking, because isn't that what we were doing 30 years ago? Was that a practice at your institution?
Wiswell: Good point. In my institution we've got some wonderful therapists who stay current with the medical literature and are interested in this. As part of a quality-improvement initiative we have been using early nasal CPAP, immediately after birth, even in the smallest of premature infants. And we've had promising results: our frequency of BPD is significantly lower. Essentially, though, we are comparing the two time periods before and after this approach, so it is not a randomized controlled trial. With this anecdotal experience we appear to be doing pretty well in my hospital, but what does that mean, without it being a randomized controlled trial? Not a lot.
Brown:
The substudy from the SUP-PORT trial was oxygen. In San Diego it definitely affected the management of oxygen saturation, and it changed our parameters when we saw the negative effect on mortality with lower saturation. We originally changed practice patterns without evidence, and later discovered we'd been doing harm, as with some other practices, such as steroids for babies. Are there plans for follow-up studies?
Wiswell: I think one or two others are looking at long-term outcomes in babies with lower saturation. You bring up a really good point, that everyone was expecting the opposite: that the lower-saturation group would do better, but that group had worse outcomes.
Brown: I thought it dovetailed well with your slides that showed that mortality has gone up and retinopathy of prematurity has gone down.
Wiswell: Yeah.
Cheifetz: I have not worked in a delivery room setting for many years, but I have heard my neonatal colleagues debating room air versus 100% oxygen for neonatal resuscitation. From a distance, I have always wondered why it is either 21% or 100% oxygen? Why not 30% or 50%? It was good to see the recommendation that blended oxygen is a recommended option. Is blended oxygen becoming the dominant approach?
Wiswell: I think most delivery rooms are starting at an F IO 2 of 0.4 or 0.5 and titrating from there after seeing the response over several minutes and how the child looks clinically: if heart rate is up and they're doing well. In the delivery room I think it's good to have an oxygen saturation monitor placed soon after delivery, and most delivery rooms in the United States should be able to do that now. I think titrating oxygen is the best approach, and I doubt there's going to be any one F IO 2 that's best in all circumstances.
